Company Update (NYSE:MRK): Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the randomized, pivotal Phase 3 study investigating KEYTRUDA® compared to ipilimumab in the first-line treatment of . . . → Read More: Company Update (NYSE:MRK): Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early Similar Articles: Company Update: Merck & Co Inc (NYSE:MRK) – Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Present at the 35th Annual Cowen Health Care Conference Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose "breakthrough" status